Join ISPOR  | Sign up for mailing List  | Follow Us: LinkedIn Twitter Facebook YouTube
ISPOR Meetings & Conferences

Schedule
Wednesday, May 27
8 - 5PMRegistration
10 - 5PMPersonnel Placement
1 - 1:15PMWelcome

James Smeeding RPh, MBA, Director, Center for Pharmacoeconomics Studies,
University of Texas, College of Pharmacy, ISPOR President


1 - 3PMFirst General Session

"Are the Current Methodology and Dissemination Information Techniques Useful for Health Care Decision-makers?"
Moderator: Donald Young MD, Vice President, American Association of Health Plans

Keynote Speaker: David Banta MD, MPH, Senior Researcher, Netherlands Organization for Applied Scientific Research
Keynote Address: "The Usefulness of Current Methods and Dissemination Techniques for Public Policy Decisions"

"The Decision-analytic Approach: Useful Tool or Absolute Necessity in Informing Health Care Decision-making"
John Hutton , Vice President of European Operations, MEDTAP International

"Research on Drug Effectiveness (or is it Efficacy?)"
Stuart C. Hartz ScD, President, Medical Research International

"The Good, the Bad, and the Irrelevant: What Makes Economic Research Useful to Decision-makers"
Mark Zitter MBA, Chief Executive Officer, The Zitter Group


3:30 - 5PMContributed Podium Presentations

"ECONOMIC AND OUTCOMES ISSUES IN MENTAL HEALTH"

THE ECONOMIC BURDEN OF ALZHEIMER'S DISEASE TO MEDICAID IN CALIFORNIA ("MEDI-CAL") Menzin J, Lang K, Friedman M, Neumann P, Boston Health Economics, Inc., Billerica, MA, Harvard School of Public Health, MA USA

COST IMPACT OF USING OLANZAPINE AT A VETERANS AFFAIRS MEDICAL CENTER
Weiss MA, McCollum M. Department of Veterans Affairs Medical Center, Denver CO, USA

COMPARISON OF SUMATRIPTAN (IMITREX®) AND OVER-THE-COUNTER (OTC) MEDICATION USE ACCORDING TO MIGRAINE SEVERITY
Yuran TE1, Schaffer M1, Lofland JH1, Johnson NE1, Johnson KA2, 1Thomas Jefferson University, Philadelphia, PA, USA 2HealthAmerica of Pennsylvania Inc., Pittsburgh, PA, USA

SSRI ANTIDEPRESSANT USE PATTERNS AND THEIR RELATION TO CLINICAL GLOBAL IMPRESSIONS SCORES: A NATURALISTIC STUDY
Hylan TR1, Meneades L1, Crown WH3, Sacristan1, JA, Gilaberte I3, Montejo AL2, 1Eli Lilly and Company, Indianapolis, IN USA; 2Hospital Universitario, Salamanca, Spain; 3The MEDSTAT Group, Cambridge, MA USA.

SSRI ANTIDEPRESSANT USE IN PRIMARY CARE IN THE UNITED KINGDOM: A MULTIVARIATE ANALYSIS
Hylan TR1, Donoghue JM2, Dunn RL3, Ozminkowski RJ3. 1Eli Lilly and Company, Indianapolis, IN USA; 2Wirral Hospital, Merseyside, UK; 3The MEDSTAT Group, Ann Arbor, MI, USA.

EVALUATION OF ANTIDEPRESSANT UTILIZATION PATTERNS AND ASSOCIATED DEPRESSION DIAGNOSES AMONG PATIENTS IN A NATIONAL MANAGED CARE ORGANIZATION
Way K1, Brintnall EO2, Whitehouse DJ2, Young CH1, Gregor KJ1, Hughes T1, 1PCS Health Systems, Inc., Scottsdale, AZ. 2HCC Behavioral Care, Eden Praire, MN, USA

"ECONOMIC AND OUTCOMES ISSUES IN CARDIOVASCULAR DISEASE"

ECONOMIC OUTCOMES OF CAROTID ENDARTERECTOMY FOR STROKE
Patterson HK1 and Seltzer J2, 1SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA, 2Premier Research Worldwide, Philadelphia, PA, USA

COST-EFFECTIVENESS AND ECONOMIC EFFICIENCY: THE CASE OF STATIN THERAPY IN SECONDARY PREVENTION OF CORONARY HEART DISEASE
Russell MW, Huse DM, Miller JD, Hartz SC, Medical Research International, Burlington, MA, USA

ADHERENCE TO HYPERTENSION THERAPY: THE EFFECT OF INITIAL DRUG CHOICE
Caro JJ1, Speckman JL1, Salas M1, Raggio G1, Jackson JD2. 1Caro Research, Boston, MA,
2Bristol-Myers Squibb, Princeton, NJ, USA

COST-EFFECTIVENESS OF A PHARMACOLOGICAL APPROACH TO RESTENOSIS PROPHYLAXIS
Schömig A1, Schwicker D2, Darcis T3, Banz K4, Serruys PW5. 1Universität München, München, Germany; 2Parpexel International, Alexandria VA, USA; 3UCB Pharm SA, Belgium; 4Health Econ Ltd.Basle, Switzerland; 5University Rotterdam, Rotterdam, The Netherlands

EFFECT OF COMPLIANCE ON HEALTH AND ECONOMIC OUTCOMES: ROLE OF CONJUGATED ESTROGEN ON DEPRESSION AND CARDIOVASCULAR DISORDERS.
Heaton AH1, Flinner A1, Martin SL1, Emmett KE2, Buatti MC2; 1Pharmacy Gold, Eagan, MN, USA; 2Wyeth-Ayerst Laboratories, Philadelphia, PA, USA

CONFOUNDING BY INDICATION IN CALCIUM CHANNEL BLOCKER TREATMENT OF HYPERTENSION OR ANGINA
Mallick R1, Leader S1, Roht L2, 1Pracon, Reston, VA, USA; 2Hoechst Marion Roussel, Kansas City, MO, USA


5 - 6PMPlenary Speaker and ISPOR Awards Presentation

Plenary Speaker: Robert Brook MD, ScD, Vice President, RAND Health Program
Plenary Presentation: "Health Outcomes Research: Past, Present, and Future"


6 - 7PMISPOR Opening Day Reception


Third Annual International Meeting Main Page